We are pleased to announce that Sandoz Inc, a division of Novartis, has received FDA approval for ZIEXTENZO (pegfilgrastim-bmez). As you may be aware, ZIEXTENZO, a biosimilar of Neulasta™, is a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

With the approval of ZIEXTENZO, Sandoz is the first and only company to offer a short- and long-acting G-CSF biosimilar portfolio supported by manufacturing experience and robust patient services.

ZIEXTENZO is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia